文献速递神经MR

在OPERA试验中联合MRI T1无强化与对比强化多发性硬化病灶的深度学习分割

Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials.
PubMed 文献 · Radiology · 2021-12-14

基于OPERA多中心复发型多发性硬化试验的MRI数据回顾性开发联合与单独U-Net深度学习模型,用于自动分割T1无强化和对比强化病灶。联合模型对T1对比强化病灶分割Dice为0.77、无强化病灶为0.74,联合训练改善了≤0.06 mL小强化病灶的检测(AUC 0.87 vs 0.75,P < .001)。两种模型均能检出与人工评估一致的奥瑞珠单抗治疗反应。

要点

  • 联合U-Net模型分割T1对比强化病灶Dice 0.77、无强化病灶Dice 0.74,假阳性率分别为0.04和0.19。
  • 联合训练对≤0.06 mL小T1强化病灶的AUC为0.87,优于单独训练0.75(P < .001)。
  • 基线T1无强化总病灶体积与临床结局相关(人工评估HR 1.12,P = .02;联合模型HR 1.11,P = .03)。

核心结论

  • 联合网络架构与训练改善了MRI T1对比强化多发性硬化病灶的分割,两种深度学习模型性能均足够高,可检出与人工评估一致的奥瑞珠单抗治疗反应。

研究设计与样本

  • 回顾性研究,在2011年8月至2015年5月大型多中心OPERA复发型多发性硬化试验的多模态MRI数据集上开发联合与单独U-Net深度学习模型。

关键影像表现/征象

  • 联合模型对T1对比强化病灶分割平均Dice为0.77、病灶真阳性率0.88、假阳性率0.04。
  • 联合模型对T1无强化病灶分割平均Dice为0.74、病灶真阳性率0.86、假阳性率0.19。

诊断标准与关键数值

  • 联合模型对≤0.06 mL的T1对比强化小病灶AUC为0.87,单独训练模型AUC为0.75(P < .001)。
  • 24周T1对比强化病灶数:人工评估奥瑞珠单抗组366例共10个病灶 vs 干扰素组355例共141个病灶(降低93%);联合模型评估奥瑞珠单抗组365例共19个病灶 vs 干扰素组354例共128个病灶(降低86%)。
  • 48周T1对比强化病灶数:人工评估奥瑞珠单抗组355例共6个病灶 vs 干扰素组317例共150个病灶(降低96%);联合模型评估奥瑞珠单抗组355例共14个病灶 vs 干扰素组317例共121个病灶(降低90%)。
  • 96周T1对比强化病灶数:人工评估奥瑞珠单抗组340例共5个病灶 vs 干扰素组294例共157个病灶(降低97%);联合模型评估奥瑞珠单抗组340例共10个病灶 vs 干扰素组294例共144个病灶(降低94%)。
  • 新发T1无强化病灶数:人工评估奥瑞珠单抗组1060次访视共504个病灶 vs 干扰素组965次访视共1438个病灶(降低68%);联合模型评估奥瑞珠单抗组1053次访视共205个病灶 vs 干扰素组957次访视共661个病灶(降低78%)。

临床应用与阅片要点

  • 深度学习模型可自动评估T1无强化与对比强化病灶负荷,性能足以复现奥瑞珠单抗较干扰素的治疗反应。
  • 联合训练可能改善小T1对比强化病灶(≤0.06 mL)的分割性能。
  • 基线T1无强化总病灶体积与临床结局相关(人工评估HR 1.12,P = .02;联合模型HR 1.11,P = .03)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Deep learning-based segmentation could facilitate rapid and reproducible T1 lesion load assessments, which is crucial for disease management in multiple sclerosis (MS). T1 unenhancing and contrast-enhancing lesions in MS are those that enhance or do not enhance after administration of a gadolinium-based contrast agent at T1-weighted MRI. Purpose To develop deep learning models for automated assessment of T1 unenhancing and contrast-enhancing lesions; to investigate if joint training improved performance; to reproduce a known ocrelizumab treatment response; and to evaluate the association of baseline T1-weighted imaging metrics with clinical outcomes in relapsing MS clinical trials. Materials and Methods Joint and individual deep learning models (U-Nets) were developed retrospectively on multimodal MRI data sets from large multicenter OPERA trials of relapsing MS (August 2011 to May 2015). The joint model included cross-network connections and a combined loss function. Models were trained on OPERA I data sets with three-fold cross-validation. OPERA II data sets were the internal test set. Dice coefficients, lesion true-positive and false-positive rates, and areas under the receiver operating characteristic curve (AUCs) were used to evaluate model performance. Association of baseline imaging metrics with clinical outcomes was assessed with Cox proportional hazards models. Results A total of 796 patients (3030 visits; mean age, 37 years ± 9; 521 women) from the OPERA II trial were evaluated. The joint model achieved a mean Dice coefficient of 0.77 and 0.74, lesion true-positive rate of 0.88 and 0.86, and lesion false-positive rate of 0.04 and 0.19 for T1 contrast-enhancing and T1 unenhancing lesion segmentation, respectively. Joint training improved performance for smaller T1 contrast-enhancing lesions (≤0.06 mL; individual training AUC: 0.75; joint training AUC: 0.87; P < .001). A significant ocrelizumab treatment effect (P < .001) was seen in reducing the mean number of T1 contrast-enhancing lesions at 24, 48, and 96 weeks (manual assessment at 24 weeks: 10 lesions in 366 patients with ocrelizumab, 141 lesions in 355 patients with interferon, 93% reduction; manual assessment at 48 weeks: six lesions in 355 patients with ocrelizumab, 150 lesions in 317 patients with interferon, 96% reduction; manual assessment at 96 weeks: five lesions in 340 patients with ocrelizumab, 157 lesions in 294 patients with interferon, 97% reduction; joint model assessment at 24 weeks: 19 lesions in 365 patients with ocrelizumab, 128 lesions in 354 patients with interferon, 86% reduction; joint model assessment at 48 weeks: 14 lesions in 355 patients with ocrelizumab, 121 lesions in 317 patients with interferon, 90% reduction; joint model assessment at 96 weeks: 10 lesions in 340 patients with ocrelizumab, 144 lesions in 294 patients with interferon, 94% reduction) and the mean number of new T1 unenhancing lesions across all follow-up examinations (manual assessment: 504 lesions in 1060 visits for ocrelizumab-treated patients, 1438 lesions in 965 visits for interferon-treated patients, 68% reduction; joint model assessment: 205 lesions in 1053 visits for ocrelizumab-treated patients, 661 lesions in 957 visits for interferon-treated patients, 78% reduction). Baseline T1 unenhancing total lesion volume was associated with clinical outcomes (manual hazard ratio [HR]: 1.12, P = .02; joint model HR: 1.11, P = .03). Conclusion Joint architecture and training improved segmentation of MRI T1 contrast-enhancing multiple sclerosis lesions, and both deep learning models had sufficiently high performance to detect an ocrelizumab treatment response consistent with manual assessments. ClinicalTrials.gov: NCT01247324 and NCT01412333 © RSNA, 2021 Online supplemental material is available for this article. See also the editorial by Talbott in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Krishnan, Song, Clayton, et al. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials. Radiology. 2021. PMID: 34904871. doi:10.1148/radiol.211528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。